James Haden, MD
Allergy & Immunology · Fort Worth, TXNPI 1588691125
Payments from drug & device makers
Across 294 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$876
- CSL Behring$713
- Novartis$555
- Regeneron Healthcare Solutions, Inc.$450
- GSK$448
- Pfizer$421
- plus $3K from 26 others
What the payments were for
- Food & beverage$6,03398%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 38 | $876 |
| CSL Behring | 35 | $713 |
| Novartis | 30 | $555 |
| Regeneron Healthcare Solutions, Inc. | 19 | $450 |
| GSK | 27 | $448 |
| Pfizer | 32 | $421 |
| Pharming Healthcare, Inc. | 8 | $397 |
| AstraZeneca | 21 | $361 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $251 |
| Genentech USA, Inc. | 12 | $216 |
| Kaleo, Inc. | 12 | $197 |
| Sanofi-aventis U.S. LLC | 2 | $191 |
| LEO Pharma Inc. | 9 | $150 |
| Octapharma USA, Inc. | 3 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $98 |
| Optinose US, Inc. | 5 | $87 |
| Blueprint Medicines Corporation | 3 | $81 |
| Ionis Pharmaceuticals, Inc. | 3 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| Amgen | 2 | $53 |
| Incyte Corporation | 2 | $48 |
| Azurity Pharmaceuticals, Inc. | 2 | $45 |
| Organon | 5 | $43 |
| Grifols USA, LLC | 1 | $34 |
| Lilly USA, LLC | 1 | $26 |
| Biocryst Pharmaceuticals, Inc. | 1 | $24 |
| Biocryst US Sales Co., LLC | 1 | $23 |
| Covis Pharma GmbH | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Arcutis Biotherapeutics, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Alk-abello, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,133 in reported general payments places this provider in the 45th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CinryzeC1 Esterase Inhibitor | 13 | $624,136 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 314 | $279,182 |
| Dupixent PenDupilumab | 39 | $152,653 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $134,904 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 160 | $125,582 |
| Breo ElliptaFluticasone/Vilanterol | 138 | $80,459 |
| Spiriva RespimatTiotropium Bromide | 96 | $78,500 |
| Epinephrine | 281 | $48,606 |
| Advair HfaFluticasone Propion/Salmeterol | 105 | $44,580 |
| Azelastine Hcl | 1,023 | $39,780 |
| SymbicortBudesonide/Formoterol Fumarate | 91 | $33,005 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 129 | $29,199 |
| Wixela InhubFluticasone Propion/Salmeterol | 121 | $22,768 |
| Montelukast Sodium | 2,284 | $22,677 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $20,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cinryze | $98 | $624,13613 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $448 | $393,731519 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $361 | $164,607267 claims |
| CSL BehringPrivigen | $713 | $134,90412 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $48,606281 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $62 | $13,10031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Fort Worth
- Natalia ChaimowitzFort Worth$56K
- William HowlandAustin$3.6M
- Russell PerryBeaumont$3.2M
- Barbara BaxterDallas$2.5M
- Lyndon MansfieldEl Paso$2.4M
- Dale MoharKerrville$2.3M
- Erika GonzalezSan Antonio$2.2M
- Richard WassermanDallas$1.9M
- Joseph DiazSan Antonio$1.8M
- Niran AmarWaco$840K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.